BioMarin Pharma (BMRN) Receives CRL from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. TSLA

Go back to BioMarin Pharma (BMRN) Receives CRL from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL

August 19, 2020 11:30 AM EDT

Baird analyst Michael Ulz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $140.00) while maintaining an Outperform rating after the company announced a CRL on Valrox.

The analyst commented, "Overall, we view the update as disappointing and assume at least a two-year delay in time-line."

... More